FAMAR Expands Presence with Sterile Site Acquisition in Homburg

FAMAR Group, a leading European pharmaceutical CDMO, has announced the acquisition of a sterile production site in Homburg, Germany, from MiP Pharma. This acquisition marks a significant strategic milestone for FAMAR, expanding its footprint in high-value dosage forms and enhancing its aseptic and lyophilized fill & finish capabilities. The recently modernized Homburg facility will join FAMAR’s international manufacturing network, further solidifying its commitment to flexible, high-quality, and scalable production solutions. Around 100 employees will transition to FAMAR, ensuring continuity and facilitating the development of the site into a multi-customer CDMO platform. This move is backed by MidEuropa, highlighting their dedication to supporting FAMAR's expansion into complex pharmaceutical manufacturing. For MiP Pharma, the sale allows them to concentrate on their core business areas, with the transaction securing jobs and establishing a foundation for future growth.